COL18A1 and non-small cell lung carcinoma: The fact remains that ICIs plus endostatin have outperformed ICIs plus chemotherapy in the sq-NSCLC subgroup not only by a wider margin but also by a more significant margin from a safety standpoint, regardless of the type of disease.